Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315096 | 0.85 | TNKS2 (0.34) | TGFBR1MAPK14THRBGHSRTNKS | |
| SCHEMBL314194 | 0.81 | BRD4 (0.44) | MAPK1TGFBR1APLNRMAPK14THRB | |
| SCHEMBL314997 | 0.78 | TNKS2 (0.37) | PTPN1MAPK1KDM4EGLATDP1 | |
| SCHEMBL314996 | 0.78 | TNKS2 (0.37) | PTPN1MAPK1KDM4EGLATDP1 | |
| SCHEMBL314998 | 0.78 | TNKS2 (0.37) | PTPN1MAPK1KDM4EGLATDP1 | |
| SCHEMBL3400041 | 0.76 | BRD4 (0.46) | MAPK1TGFBR1APLNRMAPK14MEN1 | |
| SCHEMBL1347857 | 0.70 | TUBB4A (0.37) | TGFBR1APLNRMAPK14THRBTNKS | |
| SCHEMBL1347558 | 0.69 | AVPR1A (0.40) | — | |
| SCHEMBL1346833 | 0.69 | TACR3 (0.41) | TGFBR1APLNRTHRBTNKSTNKS2 | |
| SCHEMBL1347545 | 0.69 | AVPR1A (0.39) | TGFBR1APLNRALDH1A1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | PTPN1 3192/4885MAPK1 833/4885KDM4E 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.